Use of ivermectin in the treatment of Covid-19: a pilot trial
et al., Toxicology Reports, doi:10.1016/j.toxrep.2021.03.003, NCT04431466 (history)
, Use of ivermectin in the treatment of Covid-19: a pilot trial, Toxicology Reports, doi:10.1016/j.toxrep.2021.03.003, NCT04431466
Very small RCT with 4 control patients and 28 ivermectin patients split across 3 different dosage levels, showing lower (non-statistically significant) ICU admission with treatment. Authors suggest that ivermectin for SARS-CoV-2 is safe and reduces symptoms and viral load, and that the antiviral effect appears to be dose-dependent. NCT04431466 (history).Retraction/censorship: this paper appears to have been censored at the request of the journal's founding editor [pubmed.ncbi.nlm.nih.gov]. An external review is mentioned but is not provided, and there is no reply from the authors, or indication that the authors were notified. Conclusions in this study are limited due to the small size, however we should consider all information in the context of the full body of research.This is the 20th of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.This is the 42nd of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
|
risk of mechanical ventilation, 85.2% lower, RR 0.15, p = 0.25, treatment 1 of 27 (3.7%), control 1 of 4 (25.0%), NNT 4.7.
|
|
risk of ICU admission, 85.2% lower, RR 0.15, p = 0.25, treatment 1 of 27 (3.7%), control 1 of 4 (25.0%), NNT 4.7.
|
|
relative improvement in Ct value, 0.8% better, RR 0.99, p = 1.00, treatment 27, control 3.
|
|
risk of no viral clearance, 11.1% higher, RR 1.11, p = 1.00, treatment 10 of 27 (37.0%), control 1 of 3 (33.3%), primary outcome.
|
|
time to viral-, 16.7% lower, relative time 0.83, treatment 27, control 3.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Pott-Junior et al., 9 Mar 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 10 authors, average treatment delay 8.0 days, dosage 200μg/kg single dose, dose varies in three arms 100, 200, 400μg/kg, trial NCT04431466 (history).
RETRACTED: Use of ivermectin in the treatment of Covid-19: A pilot trial
Toxicology Reports, doi:10.1016/j.toxrep.2021.03.003
In this randomized open-label trial pilot study we assessed the antiviral effects and safety of various doses of ivermectin in patients with mild clinical symptoms of COVID-19. Methods: Patients were randomly assigned to receive standard of care (SOC) treatment at hospital admission; SOC plus ivermectin 100 mcg/kg; SOC plus ivermectin 200 mcg/kg; or SOC plus ivermectin 400 mcg/kg. The primary assessed endpoint was the proportion of patients who achieved two consecutive negative SARS-CoV-2 RT PCR tests within 7 days of the start of the dosing period. This study was registered at ClinicalTrials.gov (NCT04431466). Results: A total of 32 patients were enrolled and randomized to treatment. SOC treatment together with ivermectin did not result in any serious adverse events. All patients exhibited a reduction in SARS-CoV-2 viral load within 7 days; however, those who received ivermectin had a more consistent decrease as compared to the SOC alone group, characterized by a shorter time for obtaining two consecutive negative SARS-CoV-2 RT PCR tests. Conclusions: Ivermectin is safe in patients with SARS-CoV-2, reducing symptomatology and the SARS-CoV-2 viral load. This antiviral effect appears to depend on the dose used, and if confirmed in future studies, it suggests that ivermectin may be a useful adjuvant to the SOC treatment in patients with mild COVID-19 symptoms.
CRediT authorship contribution statement Henrique
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.191
Alexandris, Lagoumintzis, Chasapis, Nicotinic cholinergic system and COVID-19: in silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions, Toxicol. Rep, doi:10.1016/j.toxrep.2020.12.013
Banerjee, Nandy, Dalai, Ahmed, The Battle against COVID 19 pandemic: what we need to know Before we "test fire" ivermectin, Drug Res. (Stuttg), doi:10.1055/a-1185-8913
Behera, Patro, Singh, Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: a matched case-control study, PLoS One, doi:10.1371/journal.pone.0247163
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Camprubi, Almuedo-Riera, Marti-Soler, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, PLoS One, doi:10.1371/journal.pone.0242184
Control, Prevention. CDC 2019-Novel Coronavirus (2019-Ncov) Real-Time RT-PCR Diagnostic Panel
Fajnzylber, Regan, Coxen, SARS-CoV-2 viral load is associated with increased disease severity and mortality, Nat. Commun, doi:10.1038/s41467-020-19057-5
Gonzalez Canga, Sahagun Prieto, Diez Liebana, Martinez, Sierra et al., The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
He, Lau, Wu, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat. Med, doi:10.1038/s41591-020-0869-5
Lagoumintzis, Chasapis, Alexandris, Nicotinic cholinergic system and COVID-19: in silico identification of interactions between alpha7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-v and SARS-CoV-2 spike glycoproteins, Food Chem. Toxicol, doi:10.1016/j.fct.2021.112009
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptorbinding domain attached to ACE2, Vivo, doi:10.21873/invivo.12134
Molento, COVID-19 and the rush for self-medication and self-dosing with ivermectin: a word of caution, One Health, doi:10.1016/j.onehlt.2020.100148
Padhy, Mohanty, Das, Meher, Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis, J. Pharm. Pharm. Sci, doi:10.18433/jpps31457
Pena-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19, Br. J. Clin. Pharmacol, doi:10.1111/bcp.14476
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin Is associated with Lower mortality in hospitalized patients with coronavirus disease 2019: the ICON study, Chest, doi:10.1016/j.chest.2020.10.009
Sen Gupta, Biswal, Panda, Ray, Rana, Binding mechanism and structural insights into the identified protein target of COVID-19 and importinalpha with in-vitro effective drug ivermectin, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1839564
Siddiqui, Jahan, Ashraf, Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2, J. Biomol. Struct. Dyn, doi:10.1080/07391102.2020.1802345
Telbisz, Ambrus, Mozner, Interactions of potential anti-COVID-19 compounds with multispecific ABC and OATP drug transporters, Pharmaceutics, doi:10.3390/pharmaceutics13010081
Walsh, Jordan, Clyne, SARS-CoV-2 detection, viral load and infectivity over the course of an infection, J. Infect, doi:10.1016/j.jinf.2020.06.067
Yan, Ci, Chen, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm. Res, doi:10.1007/s00011-011-0307-8
Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm. Res, doi:10.1007/s00011-008-8007-8
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.